289 related articles for article (PubMed ID: 11109640)
61. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
62. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
63. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
Vemer P; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):1841-9. PubMed ID: 25424791
[TBL] [Abstract][Full Text] [Related]
64. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente.
Black S; Lieu TA; Ray GT; Capra A; Shinefield HR
Vaccine; 2000 Dec; 19 Suppl 1():S83-6. PubMed ID: 11163469
[TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
Marbaix S; Peetermans WE; Verhaegen J; Annemans L; Sato R; Mignon A; Atwood M; Weycker D
PLoS One; 2018; 13(7):e0199427. PubMed ID: 29979689
[TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
[TBL] [Abstract][Full Text] [Related]
67. Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy.
Boccalini S; Bechini A; Gasparini R; Panatto D; Amicizia D; Bonanni P
Hum Vaccin Immunother; 2017 Feb; 13(2):417-422. PubMed ID: 27925845
[TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.
Grzesiowski P; Aguiar-Ibáñez R; Kobryń A; Durand L; Puig PE
Hum Vaccin Immunother; 2012 Oct; 8(10):1382-94. PubMed ID: 23095867
[TBL] [Abstract][Full Text] [Related]
69. [Cost effectiveness of pneumococcal vaccine (author's transl)].
Levy E
Rev Epidemiol Sante Publique; 1981; 29(2):133-53. PubMed ID: 6792664
[TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden.
Wolff E; Storsaeter J; Örtqvist Å; Naucler P; Larsson S; Lepp T; Roth A
Vaccine; 2020 Jul; 38(32):4988-4995. PubMed ID: 32536548
[TBL] [Abstract][Full Text] [Related]
71. [Cost-effectiveness of universal pneumococcal vaccination in Uruguay].
Giachetto Larraz G; Telechea Ortiz H; Speranza Mourine N; Giglio N; Cané A; Pírez García MC; Lucas Paiva L; Pallares Barrios C; Gesuele Ruggiero J
Rev Panam Salud Publica; 2010 Aug; 28(2):92-9. PubMed ID: 20963275
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.
Evers SM; Ament AJ; Colombo GL; Konradsen HB; Reinert RR; Sauerland D; Wittrup-Jensen K; Loiseau C; Fedson DS
Eur J Clin Microbiol Infect Dis; 2007 Aug; 26(8):531-40. PubMed ID: 17570001
[TBL] [Abstract][Full Text] [Related]
73. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.
Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M
Value Health; 2008; 11(5):898-903. PubMed ID: 18489504
[TBL] [Abstract][Full Text] [Related]
74. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
[TBL] [Abstract][Full Text] [Related]
75. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
[TBL] [Abstract][Full Text] [Related]
76. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
77. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
78. [Economic evaluation of pneumococcal vaccination in adults aged over 65 years in Castilla y León (SPAIN)].
López-Gobernado M; Pérez-Rubio A; López-García E; Mayo Iscar A; Cabezas Pascual C; Eiros JM
Rev Esp Geriatr Gerontol; 2019; 54(6):309-314. PubMed ID: 31307781
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
[TBL] [Abstract][Full Text] [Related]
80. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.
Neto JT; de Araujo GT; Gagliardi A; Pinho A; Durand L; Fonseca M
Hum Vaccin; 2011 Oct; 7(10):1037-47. PubMed ID: 21941088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
